FDA fast-tracks drug approvals for pharma companies, citing pediatric diseases
H.R. 10359 — To amend the Federal Food, Drug, and Cosmetic Act to permanently extend the authority of the Secretary of Health and Human Services to award priority review vouchers for rare pediatric disease products. · Filed by Gus Bilirakis (R-FL) · 5 cosponsors · Introduced Sep 14, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill would make permanent the FDA's authority to award 'priority review vouchers' for drugs treating rare pediatric diseases. These vouchers let pharmaceutical companies skip the normal FDA review queue for an unrelated drug, saving months or years. The bill extends what is currently a temporary program, benefiting drug makers developing pediatric treatments.
Why we flagged it
The bill permanently extends a regulatory incentive (priority review vouchers) that primarily benefits pharmaceutical companies by accelerating their market access. While framed around pediatric disease treatment, the vouchers are tradeable and can be applied to any drug, making this fundamentally an industry benefit mechanism.
What the text implies
- Priority review vouchers are tradeable commodities; a company developing a pediatric drug can sell its voucher to another company for use on an unrelated product, decoupling the incentive from actual pediatric benefit.
- Permanent extension removes sunset review, eliminating periodic congressional reassessment of whether the program is achieving its stated public-health goal or primarily serving industry interests.
The full analysis lists 4 implications of this text.
Who stands to gain
pharmaceutical companies developing rare pediatric disease treatments; pharmaceutical companies purchasing priority review vouchers; drug manufacturers seeking accelerated FDA approval pathways